Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients.

Soulie C, Santoro MM, Charpentier C, Storto A, Paraskevis D, Di Carlo D, Gennari W, Sterrantino G, Zazzi M, Perno CF, Calvez V, Descamps D, Ceccherini-Silberstein F, Marcelin AG.

J Antimicrob Chemother. 2019 Mar 1;74(3):614-617. doi: 10.1093/jac/dky464.

PMID:
30476106
2.

Remote subsurface ocean temperature as a predictor of Atlantic hurricane activity.

Scoccimarro E, Bellucci A, Storto A, Gualdi S, Masina S, Navarra A.

Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):11460-11464. doi: 10.1073/pnas.1810755115. Epub 2018 Oct 22.

3.

Role of subsurface ocean in decadal climate predictability over the South Atlantic.

Morioka Y, Doi T, Storto A, Masina S, Behera SK.

Sci Rep. 2018 Jun 4;8(1):8523. doi: 10.1038/s41598-018-26899-z.

4.

Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants.

Perrier M, Désiré N, Storto A, Todesco E, Rodriguez C, Bertine M, Le Hingrat Q, Visseaux B, Calvez V, Descamps D, Marcelin AG, Charpentier C.

PLoS One. 2018 Jun 1;13(6):e0198334. doi: 10.1371/journal.pone.0198334. eCollection 2018.

5.

Efficiency of HIV-2 cultures from clinical isolates is enhanced after purification by anti-CD44 microbeads.

Le Hingrat Q, Perrier M, Collin G, Drumard S, Storto A, Bertine M, Larrouy L, Matheron S, Damond F, Charpentier C, Descamps D, Visseaux B.

J Virol Methods. 2018 Jul;257:12-15. doi: 10.1016/j.jviromet.2018.03.010. Epub 2018 Mar 26.

PMID:
29588254
6.

Minority resistant variants are also present in HIV-2-infected antiretroviral-naive patients.

Storto A, Visseaux B, Bertine M, Le Hingrat Q, Collin G, Damond F, Khuong MA, Blum L, Tubiana R, Karmochkine M, Cazanave C, Matheron S, Descamps D, Charpentier C; ANRS HIV-2 CO5 Cohort.

J Antimicrob Chemother. 2018 May 1;73(5):1173-1176. doi: 10.1093/jac/dkx530.

PMID:
29415189
7.

Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen.

Charpentier C, Malet I, Andre-Garnier E, Storto A, Bocket L, Amiel C, Morand-Joubert L, Tumiotto C, Nguyen T, Maillard A, Rodallec A, Leoz M, Montes B, Schneider V, Plantier JC, Dina J, Pallier C, Mirand A, Roussel C, Signori-Schmuck A, Raymond S, Calvez V, Delaugerre C, Marcelin AG, Descamps D.

J Antimicrob Chemother. 2018 Apr 1;73(4):1039-1044. doi: 10.1093/jac/dkx511.

PMID:
29342281
8.

Understanding large-scale, long-term larval connectivity patterns: The case of the Northern Line Islands in the Central Pacific Ocean.

Mari L, Bonaventura L, Storto A, Melià P, Gatto M, Masina S, Casagrandi R.

PLoS One. 2017 Aug 15;12(8):e0182681. doi: 10.1371/journal.pone.0182681. eCollection 2017.

9.

Disparities in HIV-1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations.

Todesco E, Charpentier C, Bertine M, Wirden M, Storto A, Desire N, Grude M, Nguyen T, Sayon S, Yazdanpanah Y, Katlama C, Descamps D, Calvez V, Marcelin AG.

HIV Med. 2017 Oct;18(9):696-700. doi: 10.1111/hiv.12508. Epub 2017 Apr 26.

PMID:
28444829
10.

Facets of Arctic energy accumulation based on observations and reanalyses 2000-2015.

Mayer M, Haimberger L, Pietschnig M, Storto A.

Geophys Res Lett. 2016 Oct 16;43(19):10420-10429. Epub 2016 Oct 9.

11.

HIV-2 Vif Diversity Among Defective and Nondefective Sequences.

Bertine M, Visseaux B, Storto A, Collin G, Matheron S, Descamps D, Charpentier C; ANRS CO5 HIV-2 Cohort.

J Acquir Immune Defic Syndr. 2016 May 1;72(1):e9-e11. doi: 10.1097/QAI.0000000000000924. No abstract available.

PMID:
26689972
12.

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver DAMC, Åsjö B, Beshkov D, Coughlan S, Descamps D, Griskevicius A, Hamouda O, Horban A, Van Kasteren M, Kolupajeva T, Kostrikis LG, Liitsola K, Linka M, Mor O, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Staneková D, Stanojevic M, Van Laethem K, Zazzi M, Zidovec Lepej S, Boucher CAB, Schmit JC, Wensing AMJ; SPREAD Program, Puchhammer-Stockl E, Sarcletti M, Schmied B, Geit M, Balluch G, Vandamme AM, Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, Vandekerckhove LPR, Van den Heuvel A, Van Der Gucht B, Van Ranst M, Van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Van Laethem K, Beshkov D, Alexiev I, Lepej SZ, Begovac J, Kostrikis L, Demetriades I, Kousiappa I, Demetriou V, Hezka J, Linka M, Maly M, Machala L, Nielsen C, Jørgensen LB, Gerstoft J, Mathiesen L, Pedersen C, Nielsen H, Laursen A, Kvinesdal B, Liitsola K, Ristola M, Suni J, Sutinen J, Descamps D, Assoumou L, Castor G, Grude M, Flandre P, Storto A, Hamouda O, Kücherer C, Berg T, Braun P, Poggensee G, Däumer M, Eberle J, Heiken H, Kaiser R, Knechten H, Korn K, Müller H, Neifer S, Schmidt B, Walter H, Gunsenheimer-Bartmeyer B, Harrer T, Paraskevis D, Hatzakis A, Zavitsanou A, Vassilakis A, Lazanas M, Chini M, Lioni A, Sakka V, Kourkounti S, Paparizos V, Antoniadou A, Papadopoulos A, Poulakou G, Katsarolis I, Protopapas K, Chryssos G, Drimis S, Gargalianos P, Xylomenos G, Lourida G, Psichogiou M, Daikos GL, Sipsas NV, Kontos A, Gamaletsou MN, Koratzanis G, Sambatakou H, Mariolis H, Skoutelis A, Papastamopoulos V, Georgiou O, Panagopoulos P, Maltezos E, Coughlan S, De Gascun C, Byrne C, Duffy M, Bergin C, Reidy D, Farrell G, Lambert J, O'Connor E, Rochford A, Low J, Coakely P, O'Dea S, Hall W, Mor O, Levi I, Chemtob D, Grossman Z, Zazzi M, de Luca A, Balotta C, Riva C, Mussini C, Caramma I, Capetti A, Colombo MC, Rossi C, Prati F, Tramuto F, Vitale F, Ciccozzi M, Angarano G, Rezza G, Kolupajeva T, Vasins O, Griskevicius A, Lipnickiene V, Schmit JC, Struck D, Sauvageot N, Hemmer R, Arendt V, Michaux C, Staub T, Sequin-Devaux C, Wensing AMJ, Boucher CAB, van de Vijver DAMC, van Kessel A, van Bentum PHM, Brinkman K, Connell BJ, van der Ende ME, Hoepelman IM, van Kasteren M, Kuipers M, Langebeek N, Richter C, Santegoets RMWJ, Schrijnders-Gudde L, Schuurman R, van de Ven BJM, Åsjö B, Kran AB, Ormaasen V, Aavitsland P, Horban A, Stanczak JJ, Stanczak GP, Firlag-Burkacka E, Wiercinska-Drapalo A, Jablonowska E, Maolepsza E, Leszczyszyn-Pynka M, Szata W, Camacho R, Palma C, Borges F, Paixão T, Duque V, Araújo F, Otelea D, Paraschiv S, Tudor AM, Cernat R, Chiriac C, Dumitrescu F, Prisecariu LJ, Stanojevic M, Jevtovic D, Salemovic D, Stanekova D, Habekova M, Chabadová Z, Drobkova T, Bukovinova P, Shunnar A, Truska P, Poljak M, Lunar M, Babic D, Tomazic J, Vidmar L, Vovko T, Karner P, Garcia F, Paredes R, Monge S, Moreno S, Del Amo J, Asensi V, Sirvent JL, de Mendoza C, Delgado R, Gutiérrez F, Berenguer J, Garcia-Bujalance S, Stella N, de Los Santos I, Blanco JR, Dalmau D, Rivero M, Segura F, Elías MJP, Alvarez M, Chueca N, Rodríguez-Martín C, Vidal C, Palomares JC, Viciana I, Viciana P, Cordoba J, Aguilera A, Domingo P, Galindo MJ, Miralles C, Del Pozo MA, Ribera E, Iribarren JA, Ruiz L, de la Torre J, Vidal F, Clotet B, Albert J, Heidarian A, Aperia-Peipke K, Axelsson M, Mild M, Karlsson A, Sönnerborg A, Thalme A, Navér L, Bratt G, Karlsson A, Blaxhult A, Gisslén M, Svennerholm B, Bergbrant I, Björkman P, Säll C, Mellgren Å, Lindholm A, Kuylenstierna N, Montelius R, Azimi F, Johansson B, Carlsson M, Johansson E, Ljungberg B, Ekvall H, Strand A, Mäkitalo S, Öberg S, Holmblad P, Höfer M, Holmberg H, Josefson P, Ryding U.

Clin Infect Dis. 2016 Mar 1;62(5):655-663. doi: 10.1093/cid/civ963. Epub 2015 Nov 29.

13.

High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.

Bertine M, Charpentier C, Visseaux B, Storto A, Collin G, Larrouy L, Damond F, Matheron S, Brun-Vézinet F, Descamps D; ANRS CO5 HIV-2 Cohort.

AIDS. 2015 Apr 24;29(7):779-84. doi: 10.1097/QAD.0000000000000607.

PMID:
25985400
14.

Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.

Charpentier C, Lee GQ, Rodriguez C, Visseaux B, Storto A, Fagard C, Molina JM, Katlama C, Yazdanpanah Y, Harrigan PR, Descamps D.

J Antimicrob Chemother. 2015 Jul;70(7):2090-6. doi: 10.1093/jac/dkv048. Epub 2015 Mar 8.

PMID:
25755001
15.

Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.

Lambert-Niclot S, Charpentier C, Storto A, Fofana D, Soulie C, Fourati S, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG.

J Antimicrob Chemother. 2014 Apr;69(4):1086-9. doi: 10.1093/jac/dkt463. Epub 2013 Dec 2.

PMID:
24302653
16.

National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.

Descamps D, Assoumou L, Chaix ML, Chaillon A, Pakianather S, de Rougemont A, Storto A, Dos Santos G, Krivine A, Delaugerre C, Montes B, Izopet J, Charpentier C, Wirden M, Maillard A, Morand-Joubert L, Pallier C, Plantier JC, Guinard J, Tamalet C, Cottalorda J, Marcelin AG, Desbois D, Henquell C, Calvez V, Brun-Vézinet F, Masquelier B, Costagliola D; ANRS AC11 Resistance Study Group.

J Antimicrob Chemother. 2013 Nov;68(11):2626-31. doi: 10.1093/jac/dkt238. Epub 2013 Jun 24.

PMID:
23798669
17.

Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010.

Charpentier C, Lambert-Niclot S, Visseaux B, Morand-Joubert L, Storto A, Larrouy L, Landman R, Calvez V, Marcelin AG, Descamps D.

J Antimicrob Chemother. 2013 Oct;68(10):2197-8. doi: 10.1093/jac/dkt184. Epub 2013 Jun 7.

PMID:
23749952
18.

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.

Lambert-Niclot S, Charpentier C, Storto A, Fofana DB, Soulié C, Fourati S, Visseaux B, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG.

J Antimicrob Chemother. 2013 Jun;68(6):1237-42. doi: 10.1093/jac/dkt003. Epub 2013 Jan 29.

PMID:
23361642
19.

Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes.

Charpentier C, Lambert-Niclot S, Alteri C, Storto A, Flandre P, Svicher V, Perno CF, Brun-Vézinet F, Calvez V, Marcelin AG, Ceccherini-Silberstein F, Descamps D.

PLoS One. 2013;8(1):e54381. doi: 10.1371/journal.pone.0054381. Epub 2013 Jan 18.

20.

Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.

Charpentier C, Larrouy L, Visseaux B, Landman R, Levittas M, Storto A, Damond F, Yazdanpanah Y, Yeni P, Brun-Vézinet F, Descamps D.

J Antimicrob Chemother. 2012 Jun;67(6):1459-61. doi: 10.1093/jac/dks067. Epub 2012 Mar 1.

PMID:
22382470
21.

Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.

Visseaux B, Hurtado-Nedelec M, Charpentier C, Collin G, Storto A, Matheron S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D; ANRS CO 05 HIV-2 Cohort.

J Infect Dis. 2012 Jan 1;205(1):111-20. doi: 10.1093/infdis/jir698. Epub 2011 Dec 2.

PMID:
22140264
22.

In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.

Visseaux B, Charpentier C, Hurtado-Nedelec M, Storto A, Antoine R, Peytavin G, Damond F, Matheron S, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2).

Antimicrob Agents Chemother. 2012 Jan;56(1):137-9. doi: 10.1128/AAC.05313-11. Epub 2011 Nov 7.

23.

G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.

Ni XJ, Delelis O, Charpentier C, Storto A, Collin G, Damond F, Descamps D, Mouscadet JF.

Retrovirology. 2011 Aug 19;8:68. doi: 10.1186/1742-4690-8-68.

24.

High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger.

Charpentier C, Bellecave P, Cisse M, Mamadou S, Diakite M, Peytavin G, Tchiombiano S, Teisseire P, Pizarro L, Storto A, Brun-Vézinet F, Katlama C, Calvez V, Marcelin AG, Masquelier B, Descamps D.

Antivir Ther. 2011;16(3):429-33. doi: 10.3851/IMP1754.

PMID:
21555827
25.

Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.

Charpentier C, Roquebert B, Delelis O, Larrouy L, Matheron S, Tubiana R, Karmochkine M, Duval X, Chêne G, Storto A, Collin G, Bénard A, Damond F, Mouscadet JF, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2).

Antimicrob Agents Chemother. 2011 Mar;55(3):1293-5. doi: 10.1128/AAC.00942-10. Epub 2010 Dec 28.

26.

Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.

Descamps D, Chaix ML, Montes B, Pakianather S, Charpentier C, Storto A, Barin F, Dos Santos G, Krivine A, Delaugerre C, Izopet J, Marcelin AG, Maillard A, Morand-Joubert L, Pallier C, Plantier JC, Tamalet C, Cottalorda J, Desbois D, Calvez V, Brun-Vezinet F, Masquelier B, Costagliola D; ANRS AC11 Resistance Study Group.

J Antimicrob Chemother. 2010 Dec;65(12):2620-7. doi: 10.1093/jac/dkq380. Epub 2010 Oct 21.

PMID:
20965891
27.

Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.

Larrouy L, Chazallon C, Landman R, Capitant C, Peytavin G, Collin G, Charpentier C, Storto A, Pialoux G, Katlama C, Girard PM, Yeni P, Aboulker JP, Brun-Vezinet F, Descamps D; ANRS 127 Study Group.

Antimicrob Agents Chemother. 2010 Jul;54(7):2910-9. doi: 10.1128/AAC.00194-10. Epub 2010 May 3.

28.

[ A case of harlequin fetus].

Rinaldi G, Romondia A, Lo Storto A, Troysi C.

Minerva Pediatr. 1976 Mar 3;28(7):486-90. Italian. No abstract available.

PMID:
1004455
29.

[Histochemical findings in the adrenal glands of rabbits treated with lead and spironolactone].

Strada L, Lo Storto A, Di Nunno C, L'Abbate N, Musti M.

Med Lav. 1972 Mar-Apr;63(3):117-22. Italian. No abstract available.

PMID:
4641934
30.

[Photoplethysmograms after the cold test in angiolokinetopathies caused by vibrating tools].

Russo L, Lo Storto A, Musti M.

Boll Soc Ital Cardiol. 1972;17(7):441-8. Italian. No abstract available.

PMID:
4650840
31.

[Urinary excretion of the electrolytes sodium and potassium in experimental lead poisoning].

De Salvia F, Chiantera A, Lo Storto A, Altamura BM, L'Abbate N.

Med Lav. 1971 Oct;62(10):462-71. Italian. No abstract available.

PMID:
5146327
32.

[Penicillamine in experimental silicosis].

Lo Storto A, Strada L, L'Abbate N, De Salvia F.

Lav Um. 1971 Jan;23(1):11-22. Italian. No abstract available.

PMID:
5152864
33.

[On pneumoconiosis caused by cork (suberosis)].

Lo Storto A, De Salvia F.

Folia Med (Napoli). 1971 Jan-Feb;54(1):40-7. Italian. No abstract available.

PMID:
5142905
34.

[Histochemical findings on the steroid 3-beta-ol-dehydrogenase activity in the glomerular zone of the adrenal gland in experimental saturnism].

Strada L, Lo Storto A, Di Nunno C, L'Abbate N, Ambrosi L.

Med Lav. 1970 Nov;61(11):548-53. Italian. No abstract available.

PMID:
5508082
35.

[On the origin of "egg-shell" calcifications of the hilar lymph nodes in silicosis].

Strada L, Lo Storto A.

Med Lav. 1970 Oct;61(10):677-82. Italian. No abstract available.

PMID:
5508080
36.

[Chronic bronchitis in welders].

Lo Storto A, L'Abbate N, Polignano G, Grassi F.

Ann Med Nav (Roma). 1970 Mar-Apr;75(2):118-28. Italian. No abstract available.

PMID:
5485051

Supplemental Content

Loading ...
Support Center